Advertisement
U.S. markets closed
Advertisement

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
33.46+0.90 (+2.76%)
At close: 04:00PM EST
34.00 +0.54 (+1.61%)
After hours: 06:46PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close32.56
Open32.68
Bid33.29 x 800
Ask34.80 x 2200
Day's Range32.50 - 34.22
52 Week Range25.98 - 47.49
Volume1,481,891
Avg. Volume1,490,464
Market Cap3.281B
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-5.55
Earnings DateFeb 28, 2024 - Mar 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cytokinetics, Incorporated
    CYTK: What does Argus have to say about CYTK?CYTOKINETICS INC has an Investment Rating of SELL; a target price of $25.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose employment commenced in November 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.48 per share, which is equal to the closing price of the Company’s common stock o

  • GlobeNewswire

    Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

    Results from COURAGE-ALS to Be Presented on December 7, 2023SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023. Oral Presentations Title: Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALSPresenter: Stacy Rudnicki, M.D., V

  • TipRanks

    Goldman Sachs Says These 2 Healthcare Stocks Look Attractive — Here’s What Makes Them Each a ‘Buy’ Right Now

    A few stock segments offer stronger opportunities than the healthcare stocks. It’s not an easy sector to play, but veteran investors know that these stocks, despite their famously high overhead and long product lead times, can turn on a dime and deliver a win. It’s all tied into the nature of the biopharma industry. These companies spend fortunes researching new drugs and medical techniques – but their research can pan out in the form of multi-billion addressable markets. In the meantime, invest